QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:GENE

Genetic Technologies (GENE) Stock Forecast, Price & News

$0.82
+0.01 (+1.23%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.81
▼
$0.85
50-Day Range
$0.70
▼
$0.94
52-Week Range
$0.69
▼
$2.40
Volume
27,225 shs
Average Volume
836,053 shs
Market Capitalization
$15.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

GENE stock logo

About Genetic Technologies (NASDAQ:GENE) Stock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

GENE Price History

GENE Stock News Headlines

September 17, 2023 | fool.com
Genetic Technologies (NASDAQ: GENE)
September 12, 2023 | finance.yahoo.com
Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 30, 2023 | proactiveinvestors.com
Genetic Technologies advances commercial plans, grows revenue
August 30, 2023 | finance.yahoo.com
Annual Results – Momentum Building on our Commercial Plans
August 21, 2023 | finance.yahoo.com
Global Hereditary Genetic Testing Market Size to Reach USD 66.11 Billion in 2030 | Emergen Research
August 9, 2023 | finanznachrichten.de
Illumina: How Genetic Technologies Can Empower More People With Information
August 9, 2023 | finance.yahoo.com
Genetic Technologies Limited Announces Updated Investor Presentation
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
July 28, 2023 | seekingalpha.com
Genetic Technologies provides updates for June-quarter
July 21, 2023 | finanznachrichten.de
Genetic Technologies Ltd: Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
July 21, 2023 | finance.yahoo.com
Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
July 6, 2023 | proactiveinvestors.com.au
Genetic Technologies: revolutionising preventative healthcare
June 15, 2023 | finance.yahoo.com
Cibus Applauds the Genetic Technology (Precision Breeding) Act 2023 Passed in the United Kingdom
June 12, 2023 | benzinga.com
Direct-to-Consumer Genetic Testing Market Size is projected to reach USD 6.68 billion by 2031, growing at a CAGR of 17.30%: Straits Research
June 11, 2023 | msn.com
National would end genetic modification 'ban' if elected
June 10, 2023 | msn.com
National would end genetic modification ban if elected
May 23, 2023 | finance.yahoo.com
GeneType featured on U.S. National TV to raise Breast Cancer Awareness
May 4, 2023 | msn.com
'Genetic Havoc' - Five Reasons to Be Concerned About Gene-Edited Teff [analysis]
May 2, 2023 | benzinga.com
Genetic Technologies Stock (NASDAQ:GENE), Guidance and Forecast
May 1, 2023 | benzinga.com
Genetic Technologies Stock (NASDAQ:GENE), Dividends
March 13, 2023 | finance.yahoo.com
Back-to-back Studies Validate geneType Breast Cancer Risk Test
March 9, 2023 | benzinga.com
Preimplantation Genetic Testing Market Value To Top Us$ 1.4 Billion By 2032 : Fact.MR Study
February 27, 2023 | msn.com
Decoding genetic technologies
February 7, 2023 | finance.yahoo.com
Genetic Technologies Announces Closing of $5 Million Registered Direct Offering
February 6, 2023 | finance.yahoo.com
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
February 3, 2023 | msn.com
Why Genetic Technologies Shares Are Skyrocketing During Premarket Session
See More Headlines
Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Company Calendar

Today
9/26/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GENE
CUSIP
N/A
CIK
1166272
Web
www.gtgcorporate.com
Phone
(138) 412-7000
Fax
011-61-3-8412-7040
Employees
60
Year Founded
1989

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
3.17
Quick Ratio
3.07

Sales & Book Value

Annual Sales
$5.85 million
Price / Sales
2.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.39 per share
Price / Book
2.13

Miscellaneous

Outstanding Shares
19,240,000
Free Float
17,993,000
Market Cap
$15.95 million
Optionable
Optionable
Beta
1.50

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Simon Morriss
    Chief Exec. Officer
  • Mr. Tony Di Pietro AGIA
    B.Com, C.A., CPA, M.A.I.C.D., CFO & Company Sec.
  • Mr. Carl S. Stubbings BSc
    Chief Commercial Officer
  • Mr. Kevin Camilleri
    Chief Exec. Officer of EasyDNA
  • Mr. Paul Keith Mathieson Viney B. Bus
    FCI, FCPA, FGIA, Consultant

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













GENE Stock - Frequently Asked Questions

How have GENE shares performed in 2023?

Genetic Technologies' stock was trading at $0.93 at the beginning of the year. Since then, GENE stock has decreased by 10.9% and is now trading at $0.8290.
View the best growth stocks for 2023 here.

Are investors shorting Genetic Technologies?

Genetic Technologies saw a increase in short interest in August. As of August 31st, there was short interest totaling 64,700 shares, an increase of 22.3% from the August 15th total of 52,900 shares. Based on an average trading volume of 67,700 shares, the days-to-cover ratio is currently 1.0 days.
View Genetic Technologies' Short Interest.

What other stocks do shareholders of Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Therapeutics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX).

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are Genetic Technologies' major shareholders?

Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%).

How do I buy shares of Genetic Technologies?

Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $0.83.

How much money does Genetic Technologies make?

Genetic Technologies (NASDAQ:GENE) has a market capitalization of $15.95 million and generates $5.85 million in revenue each year.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The official website for the company is www.gtgcorporate.com. The biotechnology company can be reached via phone at (138) 412-7000, via email at ir@gtgcorporate.com, or via fax at 011-61-3-8412-7040.

This page (NASDAQ:GENE) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -